Loading clinical trials...
Loading clinical trials...
A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Placebo
AK120
+1 more
Locations
24
United States
AkesoBio Investigative Site 2003
Little Rock, Arkansas, United States
AkesoBio Investigative Site 2010
Canoga Park, California, United States
AkesoBio Investigative Site 2021
San Diego, California, United States
AkesoBio Investigative Site 2023
San Diego, California, United States
AkesoBio Investigative Site 2017
San Francisco, California, United States
AkesoBio Investigative Site 2020
Sherman Oaks, California, United States
Start Date
September 30, 2021
Primary Completion Date
May 17, 2023
Completion Date
May 17, 2023
Last Updated
February 26, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
Akesobio Australia Pty Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions